Nerisone-c

Nerisone-c Uses, Dosage, Side Effects, Food Interaction and all others data.

Chlorquinaldol was used historically as a topical antiseptic under the trade name Sterosan. It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones. Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.

Chlorquinaldol is bacteriocidal in both gram positive and gram negative bacteria. It is more effective in targeting gram positive bacteria, particularly staphylococci.

Nerisone-c
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Nerisone-c
Generic	Chlorquinaldol + Diflucortolone (Valerate)
Weight	1%w/w, 0.1%w/w
Type	Cream
Therapeutic Class
Manufacturer	Bayer Health Care
Available Country	Pakistan
Last Updated:	September 19, 2023 at 7:00 am

Uses

Chlorquinaldol was used historically as a topical antiseptic agent for skin infections. It maintains use in European countries as a combination vaginal tablet with promestriene for use in the treatment of vaginal infections.

Nerisone-c is also used to associated treatment for these conditions: Allergic Skin Reaction, Dermatitis, Skin Infections, Vaginal atrophy with infection, Allergic skin manifestations, Mycotic skin infection

How Nerisone-c works

The mechanism by which Chlorquinaldol exerts it's bacteriocidal effect is unknown. 8-hydroxyquinolines are known to be bidentate chelators of several metal ions which act as critical enzyme cofactors. However, the addition of exogenous metal ions does not appear to alter the minimum inhibitory concentration for mycobacterium tuberculosis suggesting that the primary mechanism does not rely on chelation.

Toxicity

Oral LD₅₀ (rat) - 660mg/kg

Elimination Route

There is a high degree of variability in the extent of absorption of topically applied chorquinaldol preparations. It is reported to be between 4.2 and 23.5% of the applied dose. This is quite low compared to orally administered preparations which displayed 67.6% absorption in the same study.